Fig. 6From: Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong KongCumulative incidence of other liver-related complications after the initiation of DAA therapy, stratified by the presence or absence of cirrhosisBack to article page